0001127602-22-012938.txt : 20220502
0001127602-22-012938.hdr.sgml : 20220502
20220502202436
ACCESSION NUMBER: 0001127602-22-012938
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220428
FILED AS OF DATE: 20220502
DATE AS OF CHANGE: 20220502
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AFEYAN NOUBAR
CENTRAL INDEX KEY: 0001222012
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 22884082
MAIL ADDRESS:
STREET 1: C/O FLAGSHIP PIONEERING, INC.
STREET 2: 55 CAMBRIDGE PARKWAY, SUITE 800E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-04-28
0001682852
Moderna, Inc.
MRNA
0001222012
AFEYAN NOUBAR
55 CAMBRIDGE PARKWAY, SUITE 800E
CAMBRIDGE
MA
02142
1
Common Stock
2022-04-28
4
M
0
703
0
A
2239673
D
Common Stock
3924
I
By: Flagship Pioneering, Inc.
Common Stock
11460435
I
By: Flagship Venture Labs IV LLC
Common Stock
3276339
I
By: Flagship Ventures Fund IV, LP
Common Stock
2840318
I
By: Flagship Ventures Fund IV-Rx, LP
Stock Option (Right to Buy)
142.52
2022-04-28
4
A
0
5415
0
A
2032-04-28
Common Stock
5415
5415
D
Restricted Stock Units
0
2022-04-28
4
M
0
703
0
D
Common Stock
703
0
D
Restricted stock units convert into common stock on a one-for-one basis.
Securities held by Flagship Pioneering, Inc. ("Flagship Pioneering"). Noubar B. Afeyan, Ph.D. is the CEO and a stockholder of Flagship Pioneering. Each of the reporting persons except for Flagship Pioneering disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") is a member of VentureLabs IV and also serves as its manager. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole the manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Shares held by Flagship Ventures Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
The shares subject to this restricted stock unit award vested in full on April 28, 2022.
/s/ Brian Sandstrom, as Attorney-in-Fact
2022-05-02